Skip to main content
SpringerLink
Log in

Tamsulosin offers advantages over other α1-adrenoceptor antagonists in the treatment of LUTS

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62 (1): 135–67

    Article  PubMed  CAS  Google Scholar 

  2. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19 (2): 135–61

    Article  PubMed  CAS  Google Scholar 

  3. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993 Jul; 150: 85–9

    PubMed  CAS  Google Scholar 

  4. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991 Aug 24; 338: 469–71

    Article  PubMed  CAS  Google Scholar 

  5. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guidelines No. 8. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, US Dept. of Health and Human Services, 1994

    Google Scholar 

  6. Roehrborn CG. The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia. Urol Clin North Am 1995 May; 22 (2): 445–53

    PubMed  CAS  Google Scholar 

  7. Fowler Jr FJ, Wennberg JE, Timothy RP, et al. Symptom status am quality of life following prostatectomy. JAMA 1988; 259: 3018–22

    Article  PubMed  Google Scholar 

  8. Chapple CR. Real-life experience in lower urinary tract symptom management. Drugs Today 2001; 37 Suppl. D: 47–9

    Google Scholar 

  9. Boyle P, Gould L, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405

    Article  PubMed  CAS  Google Scholar 

  10. Abrams P, Schulman CC, Vaage S, et al. Tamsulosin, a selective α1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). European Tamsulosin Study Group. Br J Urol 1995; 76: 325–36

    Article  PubMed  CAS  Google Scholar 

  11. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998; 160: 1701–6

    Article  PubMed  CAS  Google Scholar 

  12. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892–900

    Article  PubMed  CAS  Google Scholar 

  13. Schulman CC, Lock TM, Buzelin J-M, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. Urology 2001 Oct; 166: 1358–63

    Article  CAS  Google Scholar 

  14. Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). European Tamsulosin Study Group. Br J Urol 1997; 80: 597–605

    Article  PubMed  CAS  Google Scholar 

  15. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13

    Article  PubMed  CAS  Google Scholar 

  16. Boehringer Ingelheim Pharmaceuticals Incorporated. Flomax (tamsulosin) prescribing information. Ridgefield (CT): Boehringer Ingelheim, 2000

    Google Scholar 

  17. Yamanouchi Pharmaceutical Co. Ltd. Harnal (tamsulosin) prescribing information. Tokyo: Yamanouchi Pharmaceutical Co. Ltd., 2000 Jan

    Google Scholar 

  18. Yamanouchi Europe B.V. Tamsulosin: a summary of product characteristics (SmPC). Leiderdorp, The Netherlands: Yamanouchi Europe B.V., 1998 May 27

    Google Scholar 

  19. Beduschi R, Beduschi MC, Oesterling JE. Benign prostatic hyperplasia: use of drug therapy in primary care. Geriatrics 1998; 53: 24–8, 33-4, 37-40

    PubMed  CAS  Google Scholar 

  20. Cooper KL, McKiernan JM, Kaplan SA. α1-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 1999; 48: 398–405

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamsulosin offers advantages over other α1-adrenoceptor antagonists in the treatment of LUTS. Drugs Ther. Perspect 18, 1–4 (2002). https://doi.org/10.2165/00042310-200218100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218100-00001

Keywords

Search

Navigation